FORT LAUDERDALE, Fla. , Jan. 9, 2012 /PRNewswire/ — RightSmile, Inc. (Pink Sheets: RIGH) confirms reverse merger plans with BG Medical Technologies, Inc., parent company of popular medical cannabis portal, BudGenius.com.
RightSmile entered into merger discussions in October 2011. Since this time BG Medical has worked to complete an ongoing due diligence study of the public entity and market conditions. Throughout December, RightSmile complied with requests and obligations to prepare the public entity for completion of the merger along with formal exit of the RightSmile management team. Full requirements have now been met to the satisfaction of both companies. Final state and corporate filings in Florida and Nevada are progressing for the respective companies. BG Medical Technologies expects to complete the merger January 18th, 2012 . Name change and symbol change requests are to be filed shortly thereafter.
BudGenius.com has served over 240 caregivers for cannabis testing services in California , and provides safety verification and location services for over 2000 patients daily. The company expects to double businesses served and to increase user traffic to over 10,000 visitors daily by mid 2012. Advertising revenue and consumer loyalty programs are being added in Q1, expecting to increase overall revenue 300% by mid-year.
BG Medical Technologies serves its patient community through analysis of responses collected by the BudGenius.com portal in a method similar to traditional scientific trials by harnessing the power of the social Internet. These responses seek to evaluate treatment effectiveness of specific chemical ratios present within the many varieties of cannabis medicine. The resultant data is utilized by BudGenius.com to help guide patients with specific ailments to cannabis medicine varietals that have been evaluated to have a higher probability of favorable treatment.
Services will be expanded throughout 2012 to include diagnostic-support and treatment-monitoring solutions related to cannabis and herbal remedies. These will be introduced as packaged programs to physicians and qualified naturopaths. A program to formulate patient-specific neutraceutical supplements is also underway, and is expected to be introduced by year’s end. Supplements will include cannabis and non-cannabis related herbal compounds.
BG Medical Technologies is committed to providing options to patients seeking alternative and supplement treatment to traditional pharmaceutical therapy for critical ailments and general wellness.
None of the statements above made above have been evaluated by the FDA. Furthermore, none of the statements written should be construed as dispensing medical advice or making claims regarding the cure of diseases. Patients should consult a licensed health care professional before starting any supplement or medical program.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.